Chronic kidney disease (CKD) affects millions worldwide and is associated with progressive renal dysfunction and high cardiovascular morbidity and mortality. Recent advances in SGLT2 inhibitor therapy, particularly dapagliflozin, have transformed the landscape of CKD management. Beyond its glucose-lowering effects, dapagliflozin has demonstrated significant renal and cardiovascular protection, slowing progression of CKD, reducing albuminuria, and lowering risk of heart failure hospitalization across diverse patient populations.
This session will review the mechanism of action, landmark clinical trials (e.g., DAPA-CKD, DELIVER), safety consideratons, and guideline recommendations for dapagliflozin in CKD. Practical aspects including patient selection, monitoring, integration with RAAS blockade, and real-world application will be discussed. Participants will gain insight into how SGLT2 inhibitors can be used to optimize renal and cardiovascular outcomes, improve patient survival, and shape the future of CKD care.